2023-09-08 14:00:00
Orphan drug designation for MaaT Pharma
Lyon biotech MaaT Pharma announced that it has obtained orphan drug designation from the European Health Agency, the EMA, for its drug candidate MaaT033 aimed at improving the overall survival of patients who have received a hematopoietic stem cell transplant. This compound has completed its phase Ib trial in this indication. This is the first designation received by this drug, but the third for the biotech which has already obtained orphan drug status for another of its assets, MaaT013, in the United States and Europe.
Adocia collects €500,000
Following the exercise of part of its share subscription warrants, by IPF Partners, the company’s main lender, the Lyon biotech received approximately 500,000 euros, following the issue of 204,919 shares at the price of €2.44 per share. This transaction results from a contract initially signed in 2020. Adocia specializes in the treatment of metabolic diseases, with a lead compound in phase II once morest obesity. The biotech recently signed a major contract with Sanofi.
VOS INDICES
source
Crossject passes European and American audits
The biotech production sites of Dijon (Côte-d’Or) and Gray (Haute-Saône) Crossject have successfully passed new regulatory stages. On the one hand, both sites have passed an annual ISO certification audit. Furthermore, the ANSM extended the manufacturing authorization for Crossject, initially limited to clinical trials, to commercial manufacturing. The sites also received a positive conclusion from Barda, the American authority with which the biotech signed a $60 million contract for its Zeneo Midazolam, a single-use needle-free Midazolam injector intended to treat seizures. ‘epilepsy.
Selected for you
1694240319
#bref #MaaT #Pharma #Adocia #Crossject
